Cargando…

1564. Virological Suppression in People with HIV-1 (PWH) Receiving Dolutegravir/Lamivudine Was High and Similar across Age Groups despite Older PWH Having Increased Rates of Comorbidities and Polypharmacy (TANDEM Subgroup Analysis)

BACKGROUND: Aging with HIV has unique challenges, including comorbidities and drug-drug interactions. TANDEM was a retrospective medical chart review conducted across 24 US sites. This subgroup analysis examines stable-switch PWH receiving dolutegravir/lamivudine by age. METHODS: Eligible PWH were a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brogan, Andrew P, Slim, Jihad, Verdier, Gustavo, Harper, Gavin, Mycock, Katie L, Wallis, Hannah, Donovan, Cynthia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678548/ http://dx.doi.org/10.1093/ofid/ofad500.1399

Ejemplares similares

Complete Genome Sequence of Vibrio natriegens Strain PWH3a
por: Zhong, Kevin Xu, et al.
Publicado: (2023)

The evolution of physiotherapy in the multidisciplinary management of persons with haemophilia (PWH): A scoping review
por: Boccalandro, Elena A., et al.
Publicado: (2022)

1504. Weight Gain and Weight Loss Attempts among People with HIV(PWH) in Louisiana
por: Richey, Lauren, et al.
Publicado: (2023)

Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data From the PRESTIGIO Registry
por: Galli, Laura, et al.
Publicado: (2020)

89976 ASSESSING PROTEIN BIOMARKERS ROLE IN CVD RISK PREDICTION IN PERSONS LIVING WITH HIV (PWH)
por: Safo, Sandra, et al.
Publicado: (2021)

HIV care continuum outcomes among recently diagnosed people with HIV (PWH) in Washington, DC
por: Jaurretche, Maria, et al.
Publicado: (2023)

Programmed Sports Therapy (PST) in People with Haemophilia (PwH) “Sports Therapy Model for Rare Diseases”
por: Hilberg, Thomas
Publicado: (2018)

585. Hospitalization Rates and Diagnoses Vary by Age Group Among Persons with HIV (PWH) in 2014–2015
por: Fleming, Julia, et al.
Publicado: (2018)

Seropositivity, Risks, and Morbidity From Varicella-Zoster Virus Infections in an Adult PWH Cohort From 2000–2020
por: Zou, Jason, et al.
Publicado: (2022)

1400. Emergency Department (ED) Use among Persons With HIV (PWH) before and during the COVID-19 Pandemic
por: Agil, Deana, et al.
Publicado: (2022)

Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
por: Maggiolo, Franco, et al.
Publicado: (2017)

Pneumocystis jirovecii Pneumonia and Toxoplasmosis in PWH With HIV-Controlled Disease Treated for Solid Malignancies: A DAT’AIDS Study
por: Pansu, Nathalie, et al.
Publicado: (2022)

835. Improvement in Diet Attenuates Antiretroviral Therapy (ART) Associated Weight Gain in Persons with Human Immunodeficiency Virus (PWH)
por: Patel, Yesha, et al.
Publicado: (2021)

The Diagnostic Laboratory Hub: A New Health Care System Reveals the Incidence and Mortality of Tuberculosis, Histoplasmosis, and Cryptococcosis of PWH in Guatemala
por: Samayoa, B, et al.
Publicado: (2019)

77. Risk of Virologic Failure Among Treatment-experienced Suppressed People with HIV (PWH) Treated with Single-Tablet 2-Drug (2DR) vs 3-Drug (3DR) Regimens
por: Sax, Paul, et al.
Publicado: (2021)

Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
por: Maggiolo, Franco, et al.
Publicado: (2022)

Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks
por: Rolle, Charlotte-Paige, et al.
Publicado: (2023)

1023. Suppressed Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide vs. Dolutegravir/Lamivudine: Virologic Failure and Durability
por: Pierone, Gerald, et al.
Publicado: (2023)

1278. Real World Treatment Experience of Single Tablet Dolutegravir/Lamivudine in Those Naïve to Treatment with Baseline Viral Loads ≥ 100,000 copies/mL in the US
por: Benson, Paul, et al.
Publicado: (2022)

1279. Real World Treatment Experience of Treatment-Naïve People with HIV who Initiated Treatment with Single Tablet Dolutegravir/Lamivudine in a Test and Treat setting in the US.
por: Kuretski, Jennifer, et al.
Publicado: (2022)

72. Massive Weight Gain in People with HIV (PWH) Starting Initial Antiretroviral Therapy (ART): Risk Factors and Predictive Ability of Early Weight Gain
por: Phupitakphol, Tanit, et al.
Publicado: (2021)

2510. Adapting the CDC HCV viral clearance cascade methodology for persons with HIV (PWH) and HCV co-infection in 5 Health Department Jurisdictions in the US
por: Wegener, Maximilian D, et al.
Publicado: (2023)

1569. Antiretroviral Treatment (ART) Packaging Preferences and Their Impact on Adherence Among People With HIV (PWH): Findings From a Best–Worst Scaling Survey
por: Dunbar, Megan, et al.
Publicado: (2023)

1285. Systematic Literature Review of Real-world Experience with the 2-Drug Regimen Dolutegravir and Lamivudine in People with HIV Who Would Not Have Met Inclusion Criteria for the Phase 3 Clinical Program
por: Slim, Jihad, et al.
Publicado: (2022)

LB-7. Weight Change in Suppressed People with HIV (PWH) Switched from Either Tenofovir Disoproxil Fumarate (TDF) or Abacavir (ABC) to Tenofovir Alafenamide (TAF)
por: Sax, Paul, et al.
Publicado: (2020)

Michelangelo, 1475-1564 /
por: Néret, Gilles
Publicado: (2000)

DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients
por: Hidalgo-Tenorio, Carmen, et al.
Publicado: (2019)

Dolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection
por: Zamora, Francis J, et al.
Publicado: (2019)

Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH)
por: Tuan, Jessica J., et al.
Publicado: (2022)

1391. Association between Substance Abuse and Mental Illness Symptoms Screener (SAMISS) scores and HIV care cascade outcomes in newly diagnosed people with HIV (PWH) in the US South
por: Ahmed, Manal, et al.
Publicado: (2022)

1478. Evaluation Of Anal Cancer Screening Program in men who have sex with men (MSM) persons with HIV (PWH) At Two academic center HIV Clinics 2018-2022
por: Achhra, Amit, et al.
Publicado: (2023)

Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice
por: Borghetti, Alberto, et al.
Publicado: (2019)

Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV
por: Dueñas-Gutiérrez, Carlos, et al.
Publicado: (2023)

Changes in weight, body composition and metabolic parameters after switch to dolutegravir/lamivudine compared with continued treatment with dolutegravir/abacavir/lamivudine for virologically suppressed HIV infection (The AVERTAS trial): a randomised, open-label, superiority trial in Copenhagen, Denmark
por: Pedersen, Karen Brorup Heje, et al.
Publicado: (2023)

Miguel Ángel, 1475-1564 /
por: Néret, Gilles
Publicado: (2000)

Miguel Ángel, 1475-1564 /
por: Néret, Gilles
Publicado: (1998)

1567. Perspectives of People with HIV (PWH) 6 Months Following a Switch to Cabotegravir and Rilpivirine Long-acting (CAB+RPV LA) in an Observational Real-world US Study (BEYOND)
por: Dandachi, Dima, et al.
Publicado: (2023)

Real-World Effectiveness, Tolerability, and Safety of Dolutegravir/Lamivudine in Korea
por: Lee, Ki Hyun, et al.
Publicado: (2022)

Virologic Response to Dolutegravir Plus Lamivudine in People With Suppressed Human Immunodeficiency Virus Type 1 and Historical M184V/I: A Systematic Literature Review and Meta-analysis
por: Kabra, Madhusudan, et al.
Publicado: (2023)

Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project
por: Bagella, Paola, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mjnk1snk625jnmnrhqr3ncmgn8